Marcus Skribek

Marcus Skribek
Karolinska Institutet | KI · Department of Oncology-Pathology

Doctor of Medicine

About

7
Publications
472
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
19
Citations
Introduction
Attempt to dentify clinical and molecular factors that lead to increased effectiveness of ICIs in patients with advanced NSCLC.
Additional affiliations
September 2020 - present
Karolinska Institutet
Position
  • PhD Candidate
Description
  • Title: Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer - Junior supervisor in Ekman's research group
February 2019 - September 2020
Karolinska Institutet
Position
  • Researcher
January 2019 - present
Karolinska University Hospital
Position
  • Resident Oncologist
Description
  • - Seminar supervisor in cancer biology (i.e. targeted therapy), courses in oncology - Clinical supervisor for medical students - Responsible for organizing educational seminars for residents in oncology
Education
September 2021 - February 2023
Karolinska Institutet
Field of study
  • Research School for Clinicians in Epidemiology
September 2012 - August 2018
Semmelweis University
Field of study
  • Doctor of Medicine (M.D.)

Publications

Publications (7)
Article
Full-text available
Background Asian patients with metastatic non-small cell lung cancer (NSCLC) have a higher prevalence of epidermal growth factor receptor (EGFR) mutations compared to Caucasians, 30–50% and 15%, respectively. Osimertinib is a tyrosine kinase inhibitor approved as first-line therapy in patients with metastatic NSCLC harboring exon 19 or exon 21 EGFR...
Article
Full-text available
The emergence of tyrosine kinase inhibitors and immune checkpoint inhibitors has paved a new era for the management of non-small cell lung cancer, which has for many years lacked major clinical breakthroughs. Historically, 5-year overall survival remained below 5% in individuals with metastatic disease. These novel treatments have led to significan...
Article
Full-text available
There is a paucity of biomarkers for the prediction of intracranial (IC) outcome in immune checkpoint inhibitor (ICI)-treated non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM). We identified 280 NSCLC pts treated with ICIs at Karolinska University Hospital, Sweden, and University Hospital of Heraklion, Greece. The inclusi...
Article
Full-text available
Introduction We analysed patients with advanced non–small cell lung cancer (NSCLC) who were treated with immune-checkpoint inhibitors (ICIs) to address the effect of the timeline and reason for corticosteroid administration on survival outcomes. Methods We retrospectively collected clinical data of non-oncogenic driven, advanced NSCLC patients tre...
Article
Full-text available
There is lack of data addressing the intracranial (IC) efficacy of immune checkpoint inhibitors (ICIs) on brain metastases (BM) in non-small cell lung cancer (NSCLC). This patient category is underrepresented in randomized clinical trials. We retrospectively collected clinical data on patients with non-oncogenic driven NSCLC with BM who were treate...
Article
Full-text available
Background: The electrocardiogram (ECG) is a critical component of cardiovascular diagnosis. ECGs are standardly recorded in the supine position; however, due to time and space constraints as well as patient limitations, they are often performed in other positions (sitting, standing). Several studies have examined the effect of body position on ele...

Projects

Projects (3)
Project
Optimization of immune checkpoint inhibitors in the treatment of advanced NSCLC.